DexCom reported fourth quarter and fiscal year 2025 results, with full-year revenue reaching $1.26 billion, representing 13% growth on a reported basis and 12% organically. The company exceeded the high end of its guidance, driven by a 13% revenue increase in Q4, strong international growth (18% reported), and improved operational metrics including a 63.5% gross margin in Q4. CEO Jacob Steven Leach highlighted the successful US launch of the G7 15-day system and the 'early access' launch of DexCom Smart Basal, while CFO Jereme Sylvain pointed to record free cash flow surpassing $1 billion. Looking ahead to 2026, DexCom provided guidance for revenue of $5.16 to $5.25 billion (11-13% growth) and projected significant margin expansion, despite near-term investments in a new Ireland manufacturing facility.
| Metric | Value | Change |
|---|---|---|
| FY 2025 Revenue | $1.26 Billion | +13% (Reported) |
| Q4 2025 US Revenue | $892 Million | +11% |
| Q4 2025 International Revenue | $368 Million | +18% (Reported) |
| Q4 2025 Gross Margin | 63.5% | +410 bps vs 2024 |
| Q4 2025 EPS | $0.68 | N/A |
| 2026 Revenue Guidance | $5.16 - $5.25 Billion | +11% to +13% |
| 2026 Gross Margin Guidance | 63% - 64% | Expansion |
DexCom is aggressively expanding its product portfolio with the G7 15-day system, which is now available across all US channels. Management emphasized that this product offers the 'greatest accuracy to date' and reduces the burden of sensor changes. This rollout is not just a US initiative; the company plans to extend the 15-day wear time globally across the portfolio, including Stelo. This strategic move is designed to increase customer satisfaction, drive utilization, and improve gross margins over time, reinforcing DexCom's position as the 'premier glucose sensing solution.'
The company is making a significant push into the Type 2 non-insulin (T2NI) market, which CEO Leach described as a 'tremendous opportunity.' With the potential for CMS coverage that could unlock access for nearly 12 million people, DexCom is preparing for this expansion through clinical trials (RCT readout expected in mid-2026) and the launch of Smart Basal. Smart Basal is positioned as a tool to simplify workflows for prescribers and improve outcomes for patients, potentially becoming the 'new standard' for T2 basal insulin management.
International markets are identified as a major growth vector, with management stating the opportunity could eventually become 'larger than our core US market.' The company is executing a 'tiered offering' strategy, utilizing products like Dexcom One Plus to win tenders and expand access in markets with different reimbursement structures. Recent successes in France, Germany, and the UK highlight the effectiveness of this strategy. DexCom plans to add another CGM system to its international portfolio in 2026 to further penetrate these segments.
DexCom is leveraging software and AI to enhance the customer experience and drive utilization. Initiatives like 'My Dexcom Account' for support, 'DexCom Direct' for EHR integration, and AI-driven insights for Stelo (including a nutrition database) are designed to remove friction and increase customer lifetime value. Management believes that combining the best hardware with the best software experience will be the 'winning formula' for retention and growth in a competitive landscape.
The provided transcript contains significant internal numerical inconsistencies that raise questions about data integrity. Specifically, the text states full-year 2025 revenue was $1.26 billion, yet also lists Q4 US revenue ($892 million) and Q4 International revenue ($368 million), which sum to $1.26 billion for the quarter alone. This discrepancy suggests a fundamental error in the reported figures (likely confusing quarterly and annual numbers), making a true assessment of year-over-year growth difficult based solely on the text.
Management faced skepticism regarding the 2026 gross margin guidance of 63-64%. Analysts noted that this guidance implies limited expansion despite the tailwinds from the G7 15-day launch and the resolution of 2025 supply chain headwinds (freight and scrap). CFO Sylvain explained that the guide absorbs costs from the new Ireland facility startup and higher initial depreciation, but the conservative nature of the guide suggests potential execution risks or higher-than-expected costs associated with the new manufacturing footprint.
While the company is bullish on CMS coverage for Type 2 non-insulin users, the timing remains uncertain. Management stated they are 'on the verge' of a decision and expect an RCT readout in mid-2026, but the exact timing of the coverage expansion and the associated pricing dynamics (via competitive bidding) are still variables. This creates a dependency on external regulatory decisions for a significant portion of the company's future growth narrative.
The transcript indicates a temporary period of OpEx deleverage in 2026 due to the staffing and launch of the Ireland facility. While management frames this as an investment, the absorption of these costs into operating expenses before they move to COGS will pressure operating margins in the near term, requiring strict discipline on other spending to meet the 22-23% operating margin target.
Overall: Management exhibited a highly confident and energetic tone throughout the call, characteristic of a new CEO (Jacob Steven Leach) establishing his strategic vision while celebrating strong operational execution. There was a distinct emphasis on innovation and market expansion, with both Leach and Sylvain speaking in definitive terms about product launches and market opportunities. The tone remained consistent from prepared remarks into the Q&A, where they defended their 2026 guidance with detailed operational explanations.
Confidence: HIGH - Management used strong, forward-looking language such as 'early innings,' 'massive opportunity,' and 'standard for customer experience.' They provided specific metrics for product performance (e.g., 'greatest accuracy to date') and detailed financial targets, indicating a high degree of certainty in their projections and operational capabilities.
$5.16 billion to $5.25 billion (11% to 13% growth)
63% to 64%
22% to 23%
30% to 31%
Hedging & Uncertainty: Management generally used direct and confident language, particularly regarding product capabilities and market opportunities. However, hedging appeared around the timing of external events, specifically CMS coverage. Phrases like 'we anticipate,' 'if things change,' and 'we expect that to kick in really here more in 2028' were used to discuss regulatory and reimbursement timelines. This suggests confidence in internal execution (product launches, manufacturing) but caution regarding the unpredictability of government policy and payer decisions.
I believe we are still early in our journey. - Jacob Steven Leach, President and CEO
We will be the premier glucose sensing solution for all. - Jacob Steven Leach, President and CEO
We are currently building to be ready for it as if it came tomorrow. - Jereme M. Sylvain, Chief Financial Officer
There is a path for this opportunity to become even larger than our core US market. - Jacob Steven Leach, President and CEO
We do not necessarily need a record new patients to hit the the low end of our guidance. - Jereme M. Sylvain, Chief Financial Officer
This is the most accurate sensor we have ever produced. - Jacob Steven Leach, President and CEO
We are nowhere near done. There is so much more we can do. - Jacob Steven Leach, President and CEO
Analyst Sentiment: Analysts were generally inquisitive and focused on the mechanics of the 2026 guidance, particularly the conservatism in gross margins and the cadence of revenue growth. There was significant interest in the rollout of the G7 15-day product and the utilization trends for the new Type 2 non-insulin patient population.
Management Responses: Management responses were detailed and data-driven, often breaking down the components of growth (patient base, retention, price, mix) to justify their guidance. They pushed back slightly on the notion that the gross margin guide was too low, explaining the specific one-time costs associated with the Ireland facility launch. They remained patient in explaining the 'mix' impact of international tenders and US commercial coverage.
Discussion on the 2026 gross margin guidance and why it wasn't higher given the G7 15-day launch and supply chain recovery. Management explained the impact of the Ireland facility startup costs.
Deep dive into the Type 2 non-insulin (T2NI) market opportunity, including the timing of CMS coverage and the results of ongoing utilization registries.
Analysis of the G7 15-day rollout, including feedback on accuracy, adhesive performance, and the impact on sensor survival rates.
International growth strategy, specifically how DexCom plans to close the revenue gap with competitors and the role of 'tiered' product offerings like Dexcom One Plus.
Operational improvements in the supply chain, specifically the reduction in scrap rates and the shift to ocean freight to improve margins.
DexCom is executing well on its core business while simultaneously launching high-impact new products (G7 15-day, Smart Basal) that solidify its technological leadership. The company is successfully navigating a complex transition to a larger Total Addressable Market (TAM) involving Type 2 non-insulin users and international expansion. Despite the confusing numerical data in the transcript regarding revenue scale, the qualitative signals regarding product innovation, market share gains, and operational efficiency (margins, free cash flow) are strong. The upcoming CMS decision and the mid-2026 RCT readout serve as near-term catalysts. The company's strong balance sheet ($2B cash) and focus on customer experience provide resilience, making the stock a compelling growth story.
Management highlighted a positive shift in the coverage landscape, specifically noting that private payers are moving toward covering Type 2 non-insulin users and that CMS is on the verge of a decision. This regulatory tailwind is expected to unlock access for millions of potential patients.
The company reported significant improvement in supply chain operations, including the reestablishment of ocean freight routes and improved scrap rates. This operational recovery is a key driver behind the gross margin expansion seen in Q4 and expected to continue into 2026.
DexCom sees international markets as a long-term growth engine that could eventually surpass the US market. They are capitalizing on specific local wins, such as Type 2 access expansion in France, to drive share.